USPTO serial 79429882
TRANSGENE
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- JAGDEO, KARA CECILIA
- Law office
- TMO LAW OFFICE 121
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with TRANSGENE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for the prevention and the treatment of cancer and viral infections and for the prevention of cancer recurrence; anti-cancer medicines; cancer treatment compounds in the nature of pharmaceutical preparations; pharmaceutical preparations and substances for cancer treatment and prevention; immunotherapeutic pharmaceutical preparations for the prevention and the treatment of cancer; immunotherapeutic pharmaceutical preparations for the prevention and the treatment of bacterial infections; personalized immunotherapeutic pharmaceutical preparations for the prevention and the treatment of cancer, bacterial infections; pharmaceutical preparations to stimulate and modulate the immune system; pharmaceutical preparations comprising oncolytic viruses for the prevention and the treatment of cancer; medicinal preparations and pharmaceutical preparations for the treatment of infectious and genetic diseases; pharmaceutical preparations for use in chemotherapy for cancer treatment; chemotherapeutic agents being pharmaceutical preparations for the treatment of cancer and viral infections and for the prevention of cancer recurrence; Pharmaceutical substances and preparations used in oncology for the treatment of cancer and viral infections and for the prevention of cancer recurrence; vaccines; cancer vaccines; therapeutic vaccines in oncology or genetics; viral vaccines; tumor antigens being pharmaceutical preparations for the treatment of cancer and viral infections and for the prevention of cancer recurrence; viral antigens being pharmaceutical preparations for the prevention and the treatment of cancer and viral infections and for the prevention of cancer recurrence; vaccine adjuvants for medical use; Chemicals and biochemicals being medical preparations for medical and clinical use for the prevention and the treatment of cancer and viral infections and for the prevention of cancer recurrence; agents and reagents for medical or clinical use being pharmaceutical preparations for the prevention and the treatment of cancer and viral infections and for the prevention of cancer recurrence; chemical or biochemical test kits in the nature of medical diagnostic assays for testing body samples; reagents for medical and clinical use comprising preparations, agents and reagents in the nature of pharmaceutical preparations for the prevention and the treatment of cancer and viral infections and for the prevention of cancer recurrence; stem cells for medical use; clinical medical reagents; cytostatic medicines for medical use for the prevention and the treatment of cancer and viral infections and for the prevention of cancer recurrence; reagents for genetic testing of cancer tumors in medicine; preparations for detecting genetic predispositions of cancers for medical use | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 24, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 24, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 24, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 23, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 23, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 23, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 12, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 23, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 23, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 20, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 19, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 28, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 29, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 29, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 29, 2025 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Aug 7, 2025 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |